NCT03704688 - Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 9, 2018

Primary Completion Date

February 4, 2022

Study Completion Date

February 4, 2022

Conditions

Non Small Cell Lung CancerKRAS Gene Mutation

Interventions

DRUG

Trametinib 0.5 mg

0.5mg PO q daily

DRUG

Trametinib 1 MG

1.0 mg PO q daily

DRUG

Trametinib 1.5 MG

1.5mg PO q daily

DRUG

Trametinib 2 mg

2 mg PO q daily

DRUG

Ponatinib 15 MG

15mg PO q daily

DRUG

Ponatinib 30 MG

30mg PO q daily

Trial Locations (7)

10021

Memorial Sloan - Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activity), Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER